Clinical trials: Pulmonary Cancer
Malignant Pericardial Effusion, Malignant Pleural Effusion
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
This randomized clinical trial studies how well genetic sequencing-informed targeted therapy works in treating patients with stage IIIB-IV non-small cell lung cancer.
- Conditions
- Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02132884
- Testing
- cytology specimen collection procedure, therapeutic procedure, targeted therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fox Chase Cancer Center
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor…
- Trial name
- NCT01522833
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer
A Retrospective Pharmacoeconomic Study of Lung Cancer
Lung cancer is the No. cause of cancer death in Taiwan. Yet most of lung cancer are diagnosed at late stage, not amenable to surgical resection.
- Trial name
- NCT01140958
- Volunteers
- 91 people
- Sponsor
- Taipei Medical University WanFang Hospital
Non-small Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy.
- Trial name
- NCT00048087
- Testing
- ZD1839, Docetaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Exocrine Insufficiency
The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)
DETECTION. The development of a metabolomic test to diagnose and quantify pancreatic exocrine insufficiency.
- Trial name
- DETECTION (NCT05980221)
- Testing
- Metabolomics, 13C MTGT
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Lung Cancer
Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology
Lung cancer kills 160,000 patients annually; this represents 28% of all US cancer deaths. The overall year survival rate has only improved from 12% to 17% in 33 years.
- Trial name
- NCT02123797
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Baptist Memorial Health Care Corporation
Asthma
Severe Asthma Research Program
The mission of the SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time.
- Trial name
- SARP (NCT01606826)
- Where
- 8 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Advanced Lung Cancer
A Pilot Study of the VosCryoTM Breathalyser in Lung Cancer
CryoPilot is a single-centre pilot study being conducted at Weston Park Cancer Centre in Sheffield, UK. The goal of this pilot study is to determine whether small-volume exhaled breath condensate sample (EBC) obtained via a…
- Trial name
- CryoPilot (NCT07689968)
- Testing
- Expiratory Breath Condensate Collection
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Hilus Pulmonary Neoplasms
Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for Hilus Pumonis Neoplasms.
- Trial name
- IRE (NCT02430597)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Leptomeningeal Metastasis, Leptomeningeal Disease
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM).
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer
- Trial name
- FORESEE (NCT05414123)
- Testing
- CNSide
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biocept, Inc.
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Pulmonary Resection
Impact of Pulmonary Rehabilitation After Lung Resection for Cancer on Patients' Level of Anxiety and Depression
The interest of pulmonary rehabilitation for patients who underwent lung resection for cancer remains controversial. The investigators studied the effects of the RR and its impact on quality of life and level of anxiety and…
- Trial name
- NCT04985474
- Testing
- questionnaires
- Volunteers
- 133 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pneumonia, Lung Cancer
Trial of Artificial Intelligence for Chest Radiography
Randomized Clinical Trial of the impact of Chest radiograph AI-assisted triage and report generation upon clinical outcomes and an economic analysis of impact of AI decision support on radiology service delivery.
- Trial name
- ACER (NCT06456203)
- Testing
- AI
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Duke-NUS Graduate Medical School
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer
This phase I trial assesses the use of lumbar punctures to detect whether there is circulating tumor deoxyribonucleic acid (ctDNA) in the fluid that surrounds the brain and spinal cord (cerebrospinal fluid) in patients with stage…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06816979
- Testing
- Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Mesothelioma, Lung Neoplasms
Chest Wall Motion Analysis in Disease
Breathing movements, called chest wall motion, are very complex. The investigators are studying how movement of the abdomen, ribs and diaphragm contribute to breathing and how this differs with different diseases in the chest.
- Conditions
- Mesothelioma, Lung Neoplasms, Surgery, Cystic Fibrosis
- Trial name
- CWM (NCT02958683)
- Testing
- Chest wall motion analysis
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Heart of England NHS Trust
Nonsmall Cell Lung Cancer
CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology
Lung cancer remains the leading cause of cancer related mortality worldwide, with more than 1.5 million related deaths annually.
- Trial name
- NCT03940846
- Testing
- Virtual biopsy
- Where
- Netherlands
- Volunteers
- 650 people
- Sponsor
- Maastricht University
Small Cell Lung Cancer
Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment
The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line…
- Trial name
- TransCPC (NCT03419286)
- Volunteers
- 62 people
- Sponsor
- University Hospital, Grenoble
Lung Cancer
Postoperative Pain After Single Port, Two Ports and Three Ports VATS Lobectomy
This single-center, prospective, randomized controlled trial was designed to assess and compare the postoperative pain after VATS lobectomy performed though one, two and three incisions.
- Trial name
- NCT03228056
- Testing
- pain intensity measured in VAS scale
- Where
- 2 sites in Poland
- Volunteers
- 90 people
- Sponsor
- Pulmonary Hospital Zakopane
Lung Cancer
Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in preventing brain metastases in patients with limited-stage small cell lung…
- Trial name
- NCT00057746
- Testing
- Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
- Where
- 222 sites in United States, Canada
- Volunteers
- 265 people
- Sponsor
- Radiation Therapy Oncology Group
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm
NCI COVID-19 in Cancer Patients, NCCAPS Study
This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04387656
- Testing
- Biospecimen Collection, Data Collection, Quality-of-Life Assessment
- Where
- 932 sites in United States, Canada and 1 more
- Volunteers
- 1,877 people
- Sponsor
- National Cancer Institute (NCI)